Evidence map›Paper›PMID 37598662›Full record

SynthesisEuropean surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes2023

Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn's Disease Patients.

Lingna Li, Ke Jiang, Dandi Lou, Mengting Zhang, Yetan Shi, Jingyi Shen, Xiaojun Fu

Open access · diamondAbstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lingna LiPharmacy Department, The Affiliated Hospital of Ningbo University, LiHuiLi Hospital, Ningbo, China.
Ke JiangThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Dandi LouThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Mengting ZhangThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Yetan ShiThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Jingyi ShenThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Xiaojun FuNursing Department, Ningbo No. 2 Hospital, Ningbo, China.
Zhejiang Chinese Medical University · CNNingbo Medical Center Lihuili Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe impact of ustekinumab (UST) therapy on surgical complications in patients with Crohn's disease (CD) remains controversial. The aim of this meta-analysis is to explore the link between these two.

methodsDatabases (PubMed, Web of Science, Cochrane, and Springer Link) were searched until April 2022. Studies of CD patients who received UST and no UST prior to surgery (including no biological therapy, anti-tumor necrosis factor-α [anti-TNF-α] agent, and vedolizumab [VDZ]) were included. Primary outcomes included overall complications, infectious complications, and noninfectious complications.

resultsNine studies totaling 3,225 CD patients were enrolled; 332 patients received UST treatment. There was no evidence of difference in the overall complications (odds ratio [OR] = 0.84, p = 0.37, 95% confidence interval [CI] = [0.57-1.23], I2 = 40%) between CD patients who had UST treatment preoperatively and those who had no UST treatment. There was no evidence of a difference in infectious complications (OR = 1.15, p = 0.35, 95% CI = [0.86-1.53], I2 = 2%). Additionally, there was no significant evidence of difference between these groups in terms of noninfectious complications and death. Specifically, there was no evidence of difference in overall complications, infection complications (including wound complications, sepsis, abscess, and anastomotic leakage), and noninfection complications (ileus, readmission, and return to operation), compared with no biological therapy and anti-TNF-α agents. At the same time, no significant evidence of difference was discovered in the comparison of preoperative UST and VDZ therapy in terms of overall complications, infectious complications (sepsis and abscess), and noninfectious complications (intestinal obstruction, readmission, and recovery surgery).

conclusionIn general, compared with other biological agents, preoperative use of UST in the treatment of CD patients is usually safe and does not increase surgical complications.

Indexed as

Crohn DiseaseSepsisAbscessHumansRetrospective StudiesTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsUstekinumabTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsUstekinumabComplicationsCrohn’s diseaseMeta-analysisSurgicalUstekinumab

Identifiers

PMID37598662
PMCPMC10733938
OpenAlexW4386019765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.